AbbVie Inc (ABBV): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

AbbVie ( ABBV) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.4%. By the end of trading, AbbVie fell $1.52 (-3.0%) to $49.10 on average volume. Throughout the day, 8,149,188 shares of AbbVie exchanged hands as compared to its average daily volume of 6,698,500 shares. The stock ranged in price between $48.93-$50.87 after having opened the day at $50.35 as compared to the previous trading day's close of $50.62. Other companies within the Health Care sector that declined today were: Ohr Pharmaceutical ( OHRP), down 18.2%, Sorrento Therapeutics ( SRNE), down 16.5%, Spectranetics Corporation ( SPNC), down 11.9% and Galmed Pharmaceuticals ( GLMD), down 9.4%.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $83.3 billion and is part of the drugs industry. Shares are down 4.2% year to date as of the close of trading on Monday. Currently there are 4 analysts that rate AbbVie a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and generally higher debt management risk.

On the positive front, Karyopharm Therapeutics ( KPTI), up 15.0%, Bind Therapeutics ( BIND), up 14.7%, Celladon ( CLDN), up 13.9% and Biolase ( BIOL), up 10.9% , were all gainers within the health care sector with Jazz Pharmaceuticals ( JAZZ) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

The Hottest Investing Plays in the Booming Weed Industry for 2018

The Hottest Investing Plays in the Booming Weed Industry for 2018

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

AbbVie Appears Ready to Start a New Advance at Any Time

AbbVie Appears Ready to Start a New Advance at Any Time

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here